Quince Therapeutics (NASDAQ: QNCX) has announced the appointment of leading immunologist, Hassan Abolhassani, MD, PhD, to its scientific advisory board (SAB).
Dr. Abolhassani currently serves as assistant professor of clinical immunology and research specialists in the department of medical biochemistry and biophysics at the Karolinska Institutet in Stockholm, Sweden.
In a statement, Dr. Mauro Magnani, PhD, chair of Quince’s SAB, commented, “Quince is excited to welcome leading immunologist and researcher Dr. Abolhassani as a new member of our SAB. Given his notable work in immunodeficiency disorders, as well as the rare pediatric neurodegenerative disease Ataxia-Telangiectasia, we expect to benefit from his unique insight and expertise as the SAB continues to support Quince as the company advances its potentially breakthrough ability to deliver corticosteroid treatment without toxicities with its lead asset eDSP.”
Dr. Hassan Abolhassani remarked, “It is an honor to join Quince’s SAB at this exciting time as the company prepares to report topline results in the first quarter of 2026 evaluating the company’s lead asset, eDSP, for the treatment of patients with A-T. I look forward to collaborating with the distinguished members of Quince’s management team, board of directors, and SAB to support the advancement of eDSP for the treatment of not only A-T but for additional potential immunological and autoimmune focused rare disease indications.”
